Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01303146
Other study ID # P070805
Secondary ID
Status Completed
Phase Phase 2
First received February 23, 2011
Last updated February 23, 2011
Start date October 2008
Est. completion date April 2010

Study information

Verified date February 2011
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

There is currently no effective treatment for late infantile MLD once clinical symptoms are evident. METAZYM is a recombinant human arylsulfatase A developed for an intravenous ERT for the treatment of late infantile MLD. The overall objective of this study is to evaluate the efficacy and safety of intravenous rhASA treatment in a patient with late infantile MLD who had previously received hematopoietic stem cell transplantation (HCT).


Description:

Metachromatic Leukodystrophy (MLD) is a rare autosomal recessive disorder caused by the deficiency of the Arylsulfatase A enzyme (ARSA), resulting in accumulation of galactosyl sulfatide (cerebroside sulfate), a major constituent of the myelin sheath. Accumulation of galactosyl sulfatides leads to a progressive degeneration of the white matter in the central and peripheral nervous system (CNS, PNS) and neuronal degeneration. The late infantile form of MLD, which usually is diagnosed in the second year of life, is the most frequent and severe form of the disease. The prognosis is severe, leading to vegetative stage or death within few years after the diagnosis. There is no treatment for patients affected with this early onset form of the disease. In patients with late-onset MLD (juvenile and adult forms), allogeneic hematopoietic stem cell transplantation can stabilize the cerebral demyelination. This treatment is however inefficient in patients with late infantile MLD at a symptomatic stage. The overall objective is to evaluate the efficacy and safety of rhASA treatment in a patient with late infantile MLD who had received HCT at a presymptomatic stage of the disease. Patient will receive rhARSA (100 U/kg) intravenously every other week for a period of 18 months.


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date April 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Both
Age group 6 Months and older
Eligibility Inclusion Criteria:

- Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities.

- The patient must have a confirmed diagnosis of MLD as defined by:ARSA activity < 10 nmol/h/mg in leukocytes prior to HCT; Presence of elevated sulfatide in urine prior to HCT

- The patient must have a residual level of voluntary function (as judged by the investigator), including presence of residual cognitive function (attention, executive and visual functions) as well as the presence of residual voluntary motor function in one upper or lower limb as a minimum.

- The patient must have an age at the time of screening = 6 months

- The patient must have had onset of symptoms before the age of 4 years

- The subject and his/her guardian(s) must have the ability to comply with the clinical protocol

- The patients' medical record must document that the legal guardian(s) has had independent counselling or a consultation regarding stem cell transplantation in order to assure that the guardian(s) is fully informed regarding the risks and benefits of this alternative

Exclusion Criteria:

Patient will be excluded from this study if they do not meet the specific inclusion criteria, or if any of the following criteria apply:

- Presence of a gross motor function measure (GMFM < 25)

- Presence of severe pseudo-bulbar signs (weakness and disco-ordination of tongue and swallowing muscles leading to severe difficulty with swallowing)

- Spasticity so severe to inhibit transportation

- Known multiple sulfatase deficiency

- Presence of major congenital abnormality

- Presence of known chromosomal abnormality and syndromes affecting psychomotor development

- Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition

- Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial

- Use of any investigational product within 30 days prior to study enrolment or currently enrolled in another study which involves clinical investigations

- Received ERT with rhASA from any source

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
rhARSA
intravenous infusion 100U/kg every other week for 18 months

Locations

Country Name City State
France Department of Pediatric Endocrinology and Neurology, Saint Vincent de Paul Hospital Paris

Sponsors (4)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris European Leukodystrophy Association, Shire, Zymenex A/S

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of METAZYM on peripheral nerve function by electrophysiological studies (motor and sensory nerves conduction velocities) every 6 months; every 6 months No
Primary Efficacy of METAZYM on peripheral nerve sulfatide storage and demyelination by nerve biopsy at baseline and week 26; week 26 No
Primary Efficacy of METAZYM on functional capacity by assessing motor function (GMFM) every 6 months every 6 months No
Secondary Efficacy of METAZYM on central nervous system involvement by evaluation of cognitive and neurological function, somatosensory and auditory evoked potentials, and brain MRI every 6 months; every 6 months No
Secondary Safety profile of METAZYM by monitoring AE's, vital sign parameters and physical examination findings before each injection, as well as ECGs and routine clinical laboratory tests every 3 months. every 3 months No
See also
  Status Clinical Trial Phase
Completed NCT00383448 - HSCT for High Risk Inherited Inborn Errors Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Active, not recruiting NCT04628364 - The Natural History of Metachromatic Leukodystrophy Study (HOME Study)
Enrolling by invitation NCT05368038 - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Withdrawn NCT00639132 - The Natural History of Metachromatic Leukodystrophy
Active, not recruiting NCT01801709 - Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy Phase 1/Phase 2
Completed NCT00683189 - Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy N/A
Recruiting NCT02171104 - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Active, not recruiting NCT03392987 - A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) Phase 2
Recruiting NCT02559830 - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Phase 1/Phase 2
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Completed NCT00004378 - Stem Cell Transplantation (SCT) for Genetic Diseases N/A
Active, not recruiting NCT04283227 - OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) Phase 3
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04925349 - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT01560182 - Gene Therapy for Metachromatic Leukodystrophy (MLD) Phase 1/Phase 2
Completed NCT01586455 - Human Placental-Derived Stem Cell Transplantation Phase 1